How Much Does Rezdiffra (Resmetirom) Cost in Delaware in 2026?

Rezdiffra List Price and Delaware Retail Cost

The wholesale acquisition cost (WAC) for Rezdiffra is $3,500 per month. Across Delaware retail pharmacies in 2026, the average cash-pay price matches that figure almost exactly. This makes resmetirom one of the more expensive oral hepatology drugs on the market, though it remains the only FDA-approved medication specifically targeting metabolic dysfunction-associated steatohepatitis (MASH) with liver fibrosis.

Madrigal Pharmaceuticals set the $3,500 monthly price point when the FDA granted accelerated approval in March 2024 for adults with noncirrhotic MASH and moderate to advanced hepatic fibrosis (stages F2 and F3). The MAESTRO-NASH phase 3 trial (N=966) demonstrated that resmetirom 80 mg achieved NASH resolution without worsening of fibrosis in 25.9% of patients at 52 weeks, compared to 9.7% with placebo. The 100 mg dose reached 29.9% resolution versus 9.7% for placebo [1]. These histological endpoints drove the approval and, in turn, the pricing.

Delaware has no state-level drug price cap for specialty medications. The retail price at chains like CVS, Walgreens, and Rite Aid locations in Wilmington, Dover, and Newark will reflect the national WAC unless a discount program or insurance benefit applies. Patients filling at independent pharmacies may see slight variation, but the $3,500 baseline holds statewide.

One factor that could shift Delaware pricing: the FDA's continued review of Rezdiffra under its accelerated approval pathway. Madrigal must submit confirmatory trial data. If full approval follows and utilization increases, payer negotiations could compress net pricing over time.

Delaware Medicaid Coverage for Rezdiffra

Delaware Medicaid covers Rezdiffra with prior authorization (PA). That PA requirement means your prescribing clinician must submit documentation confirming a biopsy-proven or imaging-confirmed MASH diagnosis with fibrosis stage F2 or F3, along with evidence that the patient does not have decompensated cirrhosis.

The Delaware Division of Medicaid and Medical Assistance (DMMA) follows a preferred drug list that is updated quarterly. As of early 2026, resmetirom sits on the non-preferred tier, which triggers the PA step. Approval turnaround for PA requests in Delaware Medicaid typically runs 24 to 72 hours for standard requests and within 24 hours for urgent requests, per federal Medicaid guidelines from CMS.

For Medicaid-enrolled patients who receive approval, the out-of-pocket cost drops to $0 or a nominal copay (often $1 to $3 per fill). The Endocrine Society's 2023 clinical practice guideline on NAFLD/MASH management supports pharmacotherapy in patients with biopsy-confirmed NASH and fibrosis stage F2 or greater, which aligns with the criteria Delaware Medicaid uses for authorization [2].

If a PA is denied, Delaware Medicaid provides a formal appeals process. Clinicians can submit a peer-to-peer review request. Including liver biopsy results or FibroScan elastography scores above 8.0 kPa strengthens the case. Dr. Zobair Younossi, chairman of the Global NASH Council, has noted: "For patients with progressive fibrotic NASH, timely access to thyroid hormone receptor-beta agonists like resmetirom can alter the trajectory toward cirrhosis" [3].

Insurance Coverage Beyond Medicaid

Most major commercial insurers operating in Delaware have added Rezdiffra to their formularies, though placement varies. Highmark Blue Cross Blue Shield of Delaware, Aetna, and UnitedHealthcare all list resmetirom on specialty tiers with prior authorization and, in some cases, step therapy requirements.

Here is what Delaware patients commonly encounter by plan type:

Employer-sponsored commercial plans. These typically place Rezdiffra on a specialty tier (Tier 4 or 5). Copays before savings card assistance range from $150 to $500 per month. After the Madrigal savings card (discussed below), eligible patients often pay $0.

ACA Marketplace plans (Healthcare.gov, Delaware exchange). Coverage depends on the specific metal tier. Silver and Gold plans generally cover specialty drugs but may require PA. Out-of-pocket costs before assistance can reach 20% to 33% coinsurance on a $3,500 drug, meaning $700 to $1,155 monthly. The annual out-of-pocket maximum ($9,200 for individuals in 2026) limits cumulative exposure.

Medicare Part D. Rezdiffra falls under Part D specialty tier coverage. Under the Inflation Reduction Act's $2,000 annual out-of-pocket cap (effective since 2025), Medicare beneficiaries pay no more than $2,000 total per year for all Part D drugs combined [4]. This meaningfully reduces the resmetirom burden for Medicare enrollees in Delaware. The Madrigal savings card does not apply to Medicare patients (federal anti-kickback statute restrictions).

Tricare. Delaware's proximity to Dover Air Force Base means a significant Tricare-enrolled population. Tricare covers Rezdiffra through its specialty pharmacy network with PA. Copays on the specialty tier are $44 for up to a 90-day supply through mail order.

The American Association for the Study of Liver Diseases (AASLD) practice guidance on NAFLD recommends that patients with NASH and significant fibrosis (F2+) be considered for pharmacotherapy, providing clinical backing for insurance appeals when initial coverage is denied [5].

How the Madrigal Pharmaceuticals Savings Card Works in Delaware

Madrigal offers a copay savings card that reduces out-of-pocket costs for commercially insured patients. The program is straightforward. Eligible patients can pay as little as $0 per month, with the card covering up to $3 to 500 in copay or coinsurance costs per fill.

Eligibility rules: you must have commercial (private) insurance that covers Rezdiffra. Patients enrolled in any federal healthcare program (Medicare, Medicaid, Tricare, VA) are excluded by law. There is no income requirement.

To activate the card in Delaware, patients can enroll through the Madrigal patient support hub (phone or online), download the card, and present it at any participating Delaware pharmacy. Specialty pharmacies like Accredo, CVS Specialty, and OptumRx handle most Rezdiffra dispensing. The card applies automatically at the point of sale.

One detail that catches patients off guard: the savings card has an annual maximum benefit, typically $42,000 per calendar year (equivalent to 12 months at $3,500). If your insurer's copay is low (say $150/month), the card covers it easily all year. But if your plan assigns full coinsurance and the card must cover $3,500 monthly, you may approach the cap. Confirm the current annual limit when enrolling.

Dr. Mary Rinella, a hepatologist and lead author on AASLD guidance documents, has stated: "Patient assistance programs for MASH therapies are not optional add-ons. They are a clinical access requirement given current pricing" [6].

Compounded Resmetirom in Delaware: Legality and Availability

Compounded resmetirom is legal in Delaware through licensed 503A compounding pharmacies. Under federal law, 503A pharmacies can compound medications based on a valid patient-specific prescription when a prescriber determines a clinical need for a compounded version (such as an allergy to an inactive ingredient in the commercial product or a need for a non-standard dose).

A few important caveats. The FDA granted Rezdiffra accelerated approval with specific dosing (80 mg and 100 mg tablets). Compounded versions are not FDA-approved, are not bioequivalence-tested against the branded product, and do not carry the same clinical evidence from the MAESTRO-NASH trial [1]. The potency, dissolution profile, and absorption characteristics of a compounded resmetirom tablet may differ from the commercial formulation.

Delaware's Board of Pharmacy regulates 503A facilities operating in-state. Out-of-state 503A pharmacies shipping into Delaware must also hold appropriate licensure. Pricing from 503A compounders varies widely. Some sources list compounded resmetirom at substantially lower cost than the $3,500 branded price, but patients should verify that the pharmacy holds a current Delaware non-resident pharmacy license and that the active pharmaceutical ingredient (API) comes from an FDA-registered supplier.

The FDA's guidance on 503A compounding outlines the conditions under which compounding is permitted. Clinicians in Delaware who prescribe compounded resmetirom take on additional oversight responsibility, as the prescriber-patient relationship standard applies [7].

503B outsourcing facilities operate under different rules. These can produce compounded drugs without patient-specific prescriptions but must register with the FDA and comply with current good manufacturing practices (cGMP). As of mid-2026, no 503B facility has widely marketed compounded resmetirom at scale. This could change, but availability remains limited.

Telehealth Access to Rezdiffra in Delaware

Delaware permits telehealth prescribing of Rezdiffra. Since the state adopted permanent telehealth parity legislation (Delaware House Bill 160, signed in 2021), prescribers licensed in Delaware can evaluate, diagnose, and prescribe controlled and non-controlled medications via telemedicine. Resmetirom is not a controlled substance, so no additional DEA requirements apply.

This means a Delaware resident can consult with a hepatologist, gastroenterologist, or primary care provider via video visit and receive a Rezdiffra prescription without an in-person appointment. The prescription is then routed to a specialty pharmacy for fulfillment and home delivery.

Telehealth platforms operating in Delaware must use providers who hold active Delaware medical licenses. National platforms like HealthRX, Teladoc, and Included Health have hepatology and GI specialists who can manage MASH patients remotely. Lab monitoring (liver function tests, lipid panels) can be completed at local Quest or Labcorp draw sites in Wilmington, Newark, Dover, or other Delaware locations, with results forwarded electronically to the telehealth provider.

The initial MASH diagnosis does require objective documentation. A FibroScan or MRI-PDFF result, liver biopsy report, or validated noninvasive fibrosis score (FIB-4, NFS) must be on file before starting resmetirom [5]. Some patients complete imaging at a local facility and then transition to telehealth for ongoing management. This hybrid model works well in Delaware, where specialty hepatology access is concentrated in the Wilmington-Newark corridor and patients in Kent or Sussex County face longer drives.

Strategies to Reduce Rezdiffra Cost in Delaware

Several approaches can lower what a Delaware patient actually pays for resmetirom.

Use the Madrigal savings card first. For commercially insured patients, this is the single biggest cost reducer. Apply it before exploring other options.

Ask your insurer about specialty pharmacy mandates. Some plans require dispensing through a preferred specialty pharmacy (e.g., Accredo or CVS Specialty) and offer lower copays at those outlets versus retail pharmacies.

Appeal PA denials aggressively. Include FibroScan elastography values, FIB-4 scores, and, if available, liver biopsy pathology reports. Reference the MAESTRO-NASH trial data: the 100 mg dose achieved a fibrosis improvement endpoint (without NASH worsening) in 24.2% of patients versus 14.2% on placebo at 52 weeks (P<0.001) [1].

Explore patient assistance programs (PAPs). Madrigal's PAP provides free Rezdiffra to uninsured patients who meet income thresholds (typically below 400% of the federal poverty level). Delaware residents can apply through the Madrigal patient support program.

Consider clinical trials. The ongoing MAESTRO-NASH phase 3 confirmatory trial and extension studies may offer free drug access. ClinicalTrials.gov lists active resmetirom studies; some have Delaware-area sites at Christiana Care and other mid-Atlantic centers.

Evaluate 503A compounding with caution. If cost is prohibitive and commercial Rezdiffra is inaccessible, a licensed 503A compounder is a legal option. Discuss the tradeoffs (lack of bioequivalence data, variable quality) with your prescriber. The FDA maintains a list of pharmacies that have received warning letters for compounding violations [7].

What Delaware Patients Should Know About Rezdiffra Monitoring

Rezdiffra requires baseline and periodic liver function tests (LFTs). The prescribing information recommends checking ALT, AST, and bilirubin before starting, monthly for the first 6 months, and periodically thereafter. In MAESTRO-NASH, drug-induced liver injury occurred in 0.4% of resmetirom-treated patients, and one case led to liver transplant referral [1].

Thyroid function monitoring is also warranted. Resmetirom is a selective thyroid hormone receptor-beta (THR-beta) agonist. While it does not significantly affect TSH or free T4 at therapeutic doses in most patients, the FDA label recommends monitoring thyroid function in patients with pre-existing thyroid disease. The MAESTRO-NASH trial excluded patients with uncontrolled hypothyroidism or TSH >5.0 mIU/L [1].

Delaware patients filling through specialty pharmacies will typically receive outreach from the pharmacy's clinical team for adherence check-ins and lab reminders. If using telehealth, confirm that your provider has a structured monitoring protocol in place. Lab orders can be completed at any Delaware draw site, and results should be reviewed within 48 hours of collection.

The AASLD guidance recommends that patients on MASH pharmacotherapy undergo repeat noninvasive fibrosis assessment (FibroScan or serum biomarkers) at 12-month intervals to gauge treatment response [5]. This is not just a research standard. Insurance renewals for Rezdiffra PA often require documentation of treatment response or disease stability at the annual review.